Bayer’s Nexavar misses another study endpoint, this time for breast cancer

Eric Palmer Nexavar, the blockbuster cancer drug sold by Bayer and Onyx Pharmaceuticals, has failed again in a trial for a new indication.  FiercePharma News

As legislator rails on potential Valeant-Allergan deal, Wall Street lines up to fund it

Carly Helfand It remains to be seen whether unconventional M&A tactics from Valeant's takeover partner, Bill Ackman, will help the pair get a deal for Allergan done. But in ...

Bristol-Myers inks Asia immunotherapy deal with Japan’s Ono

Emily Mullin In a deal that will build on their existing mutual relationship, Bristol-Myers Squibb and Ono Pharmaceutical have formed a pact to bring immunotherapies to market in Japan, ...

AbbVie, Shire and how $54.7B can turn a ‘no’ into a ‘yes’

Damian Garde For months, AbbVie mounted a dogged pursuit of Shire, learning from the mistakes of the now-thwarted Pfizer and maintaining its patients without letting lines go cold, ...

Merck whacks 600 sales reps as part of 8,500 bloodletting

Eric Palmer Merck is going through a complete makeover, buying and selling units at a rapid pace. And some of its employees are getting caught in its "out with the old and in with ...

Two more biotechs limp onto Wall Street with discounted debuts

Damian Garde Another hoped-for big week of biotech IPOs has come up well short, with two entrants downsizing their ambitions to make it out and a third reportedly thwarted by some bad ...

With Shire deal in the bag, Humira leap helps AbbVie hold its own

Carly Helfand AbbVie may have just struck a deal with Shire in order to diversify beyond its top drug, Humira. But that doesn't mean the drug isn't steamrolling. FiercePharma ...

Bristol-Myers beats profit estimates, thanks to strong Yervoy, Eliquis numbers

Tracy Staton Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $ 333 million in profits on $ 3.9 billion ...

Sarepta slips after new CSO is quickly pushed out

John Carroll So what happened to Sarepta's ($ SRPT) new chief scientific officer? Hired just 7 months ago, the biotech issued a one-liner in an 8-K this morning stating simply ...

Roche’s breast cancer franchise keeps delivering, with huge jumps for Perjeta, Kadcyla

Carly Helfand Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly ...

Biotech IPOs sputter amid downsizings, disappointments and white flags

Damian Garde Six biotechs were expected to go public this week, eyeing nearly $ 400 million combined, but that potential has so far amounted to one deeply discounted offering, one ...

Inovio vs. Feuerstein, Round II: Biotech claims PhII success for VGX-3100

John Carroll Shares of Inovio Pharmaceuticals jumped about 20% this morning after the biotech said it had hit the mark on the primary endpoint for its mid-stage study of VGX-3100, an ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS